GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

UnitedHealth Group's pharmacy benefits manager, OptumRx Inc., was hit with an Employee Retirement Income Security Act of 1974 ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

It turns out that obesity may be much more complicated than we thought, with the condition potentially existing in up to 11 ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

The launch of GLP-1 weight-loss drugs in India is gaining popularity. Harvard researchers share a comprehensive guidance for ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,” the study author said.

A new study reports that GLP-1 medications may improve low testosterone in men with obesity or type 2 diabetes. The findings ...